Tobira Therapeutics, Inc. Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2015 12 months to Dec 31, 2015	FY2014 12 months to Dec 31, 2014	FY2013 12 months to Dec 31, 2013
Grant revenue
Operating expenses
Research and development
General and administrative
Impairment of intangible assets
Total operating expenses
Loss from operations
Other income (expense), net
Interest income
Interest expense
Total other expense
Change in fair value of preferred stock warrant liabilities
Loss before income tax benefit (expense)
Income tax benefit (expense)
Net loss and comprehensive loss
Deemed dividend related to beneficial conversion feature of Series F convertible preferred stock
Net income (loss) available to common stockholders
Net loss attributable to preferred stockholders
Net loss attributable to common stockholders - basic and diluted
Net loss per share, basic and diluted
Weighted-average common shares outstanding, basic and diluted

Comments